Skip to Content

Medications for Ophthalmic Viscoelastic Agent

What is Ophthalmic Viscoelastic Agent:  Ophthalmic Viscoelastic Agent is a gel injected into the anterior chamber during ophthalmic surgery to maintain the depth of the chamber, protect the corneal endothelium, and stabilize the vitreous.

Medications to treat Ophthalmic Viscoelastic Agent

The following list of medications are in some way related to, or used in the treatment of this condition.

Drug name Rx / OTC Pregnancy CSA Alcohol Reviews Rating Popularity
sodium hyaluronate N N Add review Rate

Generic name: sodium hyaluronate ophthalmic

Brand names:  Amvisc, Amvisc Plus, Provisc

Drug class: ophthalmic surgical agents

For consumers: side effects

 
Amvisc N N Add review Rate

Generic name: sodium hyaluronate ophthalmic

Drug class: ophthalmic surgical agents

For consumers: side effects

 
Amvisc Plus N N Add review Rate

Generic name: sodium hyaluronate ophthalmic

Drug class: ophthalmic surgical agents

For consumers: side effects

 
Provisc N N Add review Rate

Generic name: sodium hyaluronate ophthalmic

Drug class: ophthalmic surgical agents

For consumers: side effects

 

Legend

Off Label This medication may not be approved by the FDA for the treatment of this condition.
Prescription Only / Over the Counter
Rx Prescription Only
OTC Over the Counter
Rx/OTC Prescription or Over the Counter
Pregnancy
A Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters).
B Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.
C Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use in pregnant women despite potential risks.
D There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use in pregnant women despite potential risks.
X Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use in pregnant women clearly outweigh potential benefits.
N FDA has not classified the drug.
Controlled Substances Act Schedule
N Is not subject to the Controlled Substances Act.
1 Has a high potential for abuse. Has no currently accepted medical use in treatment in the United States. There is a lack of accepted safety for use under medical supervision.
2 Has a high potential for abuse. Has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions. Abuse may lead to severe psychological or physical dependence.
3 Has a potential for abuse less than those in schedules 1 and 2. Has a currently accepted medical use in treatment in the United States. Abuse may lead to moderate or low physical dependence or high psychological dependence.
4 Has a low potential for abuse relative to those in schedule 3. It has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 3.
5 Has a low potential for abuse relative to those in schedule 4. Has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 4.
Alcohol
X Interacts with Alcohol.

Browse Drugs by Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Hide